Skip to content

Research on acute interstitial nephritis disease

Double blind randomized placebo controlled trial of corticosteroids and doxycycline in the treatment of interstitial nephritis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
SLCTR
Registry ID
SLCTR/2014/007
Enrollment
200
Registered
2014-03-31
Start date
2014-04-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute interstitial nephritis

Interventions

Patients will be randomly categorized in to four groups by computer generated randomization sequence Each category will receive two drugs as follows, starting from the day after biopsy. Category 1:

Sponsors

None
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Two or more elevated (value more than upper limit of the normal) serum creatinine values done within 3 days and 2. Normal size kidneys defined as more than 9 cm longitudinal diameter and normal anatomy on ultrasound scan 3. Age less than 60 years

Exclusion criteria

Exclusion criteria: 1. History of chronic kidney disease, diabetes mellitus, chronic hypertension, connective tissue diseases, vacuities,hyperuricemia, pyelonephritis, renal stone disease and any obstructive uropathy, polycystic kidney disease or any other known genetic disease, glomerular nephritides, snake bite, and childhood renal disease. 2. Whose current abnormal creatinine is explainable by recent exposure to nephrotoxic drugs (non-steroidal anti-inflammatory drugs, gentamicin…etc.) or toxins. 3. BP >160/100mmhg untreated or >140/90 on up to two antihypertensives 4. Two or more fasting blood sugar more than 7 mmol/l 5. UFR showing red blood cells more 50 per HPF with more than 80% dysmorphic cells or nephrotic range proteinuria or pus cells more than 100 per HPF with a positive urine culture 6. Ultrasound scan revealing unilateral renal involvement

Design outcomes

Primary

MeasureTime frame
Serum creatinine [2 weeks, one month, six month, two years]

Secondary

MeasureTime frame
1. Reaching stage 4 kidney disease 2. Death 3. Small contracted kidneys [6months, 2 years]

Countries

Sri Lanka

Contacts

Public ContactNishantha Nanayakkara

Consultant Nephrologist

nishansrikandy@yahoo.co.in0812233337

Outcome results

None listed

Source: SLCTR (via WHO ICTRP) · Data processed: Aug 9, 2026